Treatment Pattern, Financial Burden, and Outcomes in Elderly Patients with Acute Myeloid Leukemia in Korea: A Nationwide Cohort Study

被引:3
作者
Ha, Hyerim [1 ]
Jeong, Yujin [2 ]
Lim, Joo Han [1 ]
Suh, Young Ju [3 ]
机构
[1] Inha Univ Hosp, Dept Internal Med, Incheon 22332, South Korea
[2] Korea Univ, Dept Biostat, Coll Med, Seoul 02841, South Korea
[3] Inha Univ, Dept Biomed Sci, Coll Med, Incheon 22332, South Korea
关键词
acute myeloid leukemia; elderly; dose intensity; medical expenditure; LOW-DOSE CYTARABINE; QUALITY-OF-LIFE; OLDER PATIENTS; INTENSIVE CHEMOTHERAPY; PHYSICAL FUNCTION; CARE; SURVIVAL; ADULTS; AML; AGE;
D O I
10.3390/ijerph19042317
中图分类号
X [环境科学、安全科学];
学科分类号
08 ; 0830 ;
摘要
Although approximately 50% of patients with acute myeloid leukemia (AML) are diagnosed over the age of 60 years, there is currently no established consensus on the treatment of elderly AML patients. Herein, we aimed to explore the incidence, medical expenditure, treatment, and outcomes of elderly AML patients in Korea by analyzing a nationwide cohort. We employed the Korean National Health Insurance Service-Senior cohort, which represents 10% of a random selection from a total of 5.5 million subjects aged 60 years or older. AML patients were identified according to the main diagnostic criteria of acute leukemia. Treatment for AML was divided into high- (high-dose cytarabine +/- idarubicin) and low- (low-dose cytarabine or hypomethylating agents) intensity chemo-therapy and classified according to the chemotherapeutics protocol. We analyzed the survival outcomes and medical expenditures. Among 558,147 elderly patients, 471 were diagnosed with AML, and 195 (41.4%) were treated with chemotherapy. The median age was 65 years, and the median overall survival (OS) was 4.93 months (95% confidence interval, 4.47-5.43). Median OS was longer in patients undergoing chemotherapy than those in the best supportive care group (6.28 vs. 3.45 months, p < 0.001), and the difference was prominent in patients aged < 70 years. Twenty-eight (5.9%) patients received high-intensity chemotherapy, while 146 (31.0%) received low-intensity chemotherapy. The difference in median OS according to dose intensity was 4.6 months, which was longer in the high-intensity chemotherapy group (9.8 vs. 5.2 months in low-intensity group); however, the difference was not statistically significant. Patients who received high-intensity chemotherapy recorded longer hospital stays and incurred greater expenses on initial hospitalization. Elderly AML patients in Korea exhibited clinical benefits from chemotherapy. Although patients should be carefully selected for intensive treatment, chemotherapy, including low-intensity treatment, can be considered in elderly patients. Moreover, prospective studies on new agents or new treatment strategies are needed.
引用
收藏
页数:13
相关论文
共 32 条
[1]   Quality of life and physical function in adults treated with intensive chemotherapy for acute myeloid leukemia improve over time independent of age [J].
Alibhai, Shabbir M. H. ;
Breunis, Henriette ;
Timilshina, Narhari ;
Brignardello-Petersen, Romina ;
Tomlinson, George ;
Mohamedali, Hassanabbas ;
Gupta, Vikas ;
Minden, Mark D. ;
Li, Madeline ;
Buckstein, Rena ;
Brandwein, Joseph M. .
JOURNAL OF GERIATRIC ONCOLOGY, 2015, 6 (04) :262-271
[2]   Age and acute myeloid leukemia [J].
Appelbaum, FR ;
Gundacker, H ;
Head, DR ;
Slovak, ML ;
Willman, CL ;
Godwin, JE ;
Anderson, JE ;
Petersdorf, SH .
BLOOD, 2006, 107 (09) :3481-3485
[3]   Prolonged administration of low-dose cytarabine and thioguanine in elderly patients with acute myeloid leukaemia (AML) achieves high complete remission rates and prolonged survival [J].
Arthur, Christopher ;
Jeffrey, Anthony ;
Yip, Eva ;
Katsioulas, Vicki ;
Nalpantidis, Anastasios ;
Kerridge, Ian ;
Greenwood, Matthew ;
Coyle, Luke ;
Mackinlay, Naomi ;
Fay, Keith ;
Enjeti, Anoop ;
Shortt, Jake ;
Stevenson, William .
LEUKEMIA & LYMPHOMA, 2020, 61 (04) :831-839
[4]  
Batty N., 2014, J CANC RES THER, V2, P68
[5]   Economic burden of elderly patients with acute myeloid leukemia treated in routine clinical care in the United States [J].
Bell, Jill A. ;
Galaznik, Aaron ;
Farrelly, Eileen ;
Blazer, Marlo ;
Murty, Sharanya ;
Ogbonnaya, Augustina ;
Eaddy, Michael ;
Fram, Robert J. ;
Faller, Douglas, V ;
Kota, Vamsi .
LEUKEMIA RESEARCH, 2018, 71 :27-33
[6]   A randomised comparison of the novel nucleoside analogue sapacitabine with low-dose cytarabine in older patients with acute myeloid leukaemia [J].
Burnett, A. K. ;
Russell, N. ;
Hills, R. K. ;
Panoskaltsis, N. ;
Khwaja, A. ;
Hemmaway, C. ;
Cahalin, P. ;
Clark, R. E. ;
Milligan, D. .
LEUKEMIA, 2015, 29 (06) :1312-1319
[7]   A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment [J].
Burnett, Alan K. ;
Milligan, Donald ;
Prentice, Archie G. ;
Goldstone, Anthony H. ;
McMullin, Mary F. ;
Hills, Robert K. ;
Wheatley, Keith .
CANCER, 2007, 109 (06) :1114-1124
[8]   Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial [J].
Cortes, Jorge ;
Perl, Alexander E. ;
Dohner, Hartmut ;
Kantarjian, Hagop ;
Martinelli, Giovanni ;
Kovacsovics, Tibor ;
Rousselot, Philippe ;
Steffen, Bjorn ;
Dombret, Herve ;
Estey, Elihu ;
Strickland, Stephen ;
Altman, Jessica K. ;
Baldus, Claudia D. ;
Burnett, Alan ;
Kramer, Alwin ;
Russell, Nigel ;
Shah, Neil P. ;
Smith, Catherine C. ;
Wang, Eunice S. ;
Ifrah, Norbert ;
Gammon, Guy ;
Trone, Denise ;
Lazzaretto, Deborah ;
Levis, Mark .
LANCET ONCOLOGY, 2018, 19 (07) :889-903
[9]   Vosaroxin and vosaroxin plus low-dose Ara-C (LDAC) vs low-dose Ara-C alone in older patients with acute myeloid leukemia [J].
Dennis, Mike ;
Russell, Nigel ;
Hills, Robert K. ;
Hemmaway, Claire ;
Panoskaltsis, Nicki ;
McMullin, Mary-Frances ;
Kjeldsen, Lars ;
Dignum, Helen ;
Thomas, Ian F. ;
Clark, Richard E. ;
Milligan, Don ;
Burnett, Alan K. .
BLOOD, 2015, 125 (19) :2923-2932
[10]   Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML [J].
DiNardo, C. D. ;
Stein, E. M. ;
de Botton, S. ;
Roboz, G. J. ;
Altman, J. K. ;
Mims, A. S. ;
Swords, R. ;
Collins, R. H. ;
Mannis, G. N. ;
Pollyea, D. A. ;
Donnellan, W. ;
Fathi, A. T. ;
Pigneux, A. ;
Erba, H. P. ;
Prince, G. T. ;
Stein, A. S. ;
Uy, G. L. ;
Foran, J. M. ;
Traer, E. ;
Stuart, R. K. ;
Arellano, M. L. ;
Slack, J. L. ;
Sekeres, M. A. ;
Willekens, C. ;
Choe, S. ;
Wang, H. ;
Zhang, V. ;
Yen, K. E. ;
Kapsalis, S. M. ;
Yang, H. ;
Dai, D. ;
Fan, B. ;
Goldwasser, M. ;
Liu, H. ;
Agresta, S. ;
Wu, B. ;
Attar, E. C. ;
Tallman, M. S. ;
Stone, R. M. ;
Kantarjian, H. M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (25) :2386-2398